| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9957276 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US8598197 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US10189849 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US8598186 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10189850 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US10927120 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US11717523 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US11529352 | G1 THERAP | Preservation of immune response during chemotherapy regimens |
Jul, 2039
(15 years from now) | |
Cosela is owned by G1 Therap.
Cosela contains Trilaciclib Dihydrochloride.
Cosela has a total of 12 drug patents out of which 0 drug patents have expired.
Cosela was authorised for market use on 12 February, 2021.
Cosela is available in powder;intravenous dosage forms.
Cosela can be used as a method for reducing the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method for reducing the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive-stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen that includes an immune checkpoint inhibitor for extensive-stage small cell cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer.
Drug patent challenges can be filed against Cosela from 2025-02-12.
The generics of Cosela are possible to be released after 23 July, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 2025-02-12
Market Authorisation Date: 12 February, 2021
Treatment: A method for reducing the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung ca...
Dosage: POWDER;INTRAVENOUS
COSELA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic